Please assess the completion status of the following clinical trial:

Trial Title: Retapamulin as a Decolonizing Agent for MRSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admission to the general pediatric floor and pediatric intensive care units at NYU Langone Medical Center or visit to study team members at ODA clinic (Park Ave locations) in Williamsburg Brooklyn.~2. Ages 9 months to 17 years~3. Residing in the zip codes which reflect Orthodox Jewish neighborhoods where there is a current outbreak of this strain of MRSA.~4. Nasal and/or rectal culture positive for mupirocin-resistant methicillin-resistant Staphylococcus aureus (MRSA)~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Pregnant or lactating~2. Unable to appropriately consent~3. Open sores in either of the study sites (nares or rectum)~4. Recent surgical procedure to either study site (nares or rectum)~5. Concurrent use of Rifampin or Trimethoprim/Sulfamethoxazole~6. Current active MRSA infection~7. Immunocompromised~8. Presence of endotracheal tube, tracheostomy tube or other foreign body in upper airway

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Retapamulin (Type: EXPERIMENTAL): Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo used will be a triple purified pharmaceutical grade white petrolatum

Based on this trial design, predict the completion outcome and termination type (if applicable).